Investors

Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and...
More

Stock Quote
XTNT (Common Stock)
Price$2.38
Change (%) + 0.10 (4.39%)
Volume296
Data as of 02/05/16 3:49 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: XTNT.K.  Currently trading at $2.38 with a 52 week high of $4.50 and a 52 week low of $2.02.
Recent News
DateTitle 
02/03/16PR: Xtant™ Medical to Present at the Source Capital 2016 Disruptive Growth & Healthcare Conference
BELGRADE, Mont., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading regenerative medicine products and medical devices, today announced that its Chief Executive Officer, Dan Goldberger and Chief Financial Officer, John Gandolfo will present at the inaugural Source Capital 2016 Disruptive Growth & Healthcare Conference, to be held February 10-11, 2016 at the Convene Conf... 
01/12/16Xtant Medical Holdings, Inc. Reports Preliminary Fourth Quarter 2015 Financial Results
BELGRADE, Mont., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced preliminary results of its fourth quarter 2015 and preliminary full year results. Preliminary Consolidated Fourth Quarter 2015 Results Consolidated revenue for the fourth quarter 2015 was approximately $22.0 to $22.2 million, an increase of 12.7 to 13.8% compared to consolidated pro forma revenue ... 
12/15/15Xtant™ Medical Announces First Surgical Procedure With the Aranax™ Cervical Plating System
BELGRADE, Mont., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the first surgical procedure of the previously announced Aranax Cervical Plating System. The Aranax Cervical Plating System represents the latest generation of anterior cervical fixation with an enhanced locking mechanism, low profile plate features, increased screw angulation, intuitive instrumentati... 
12/09/15Xtant™ Medical Announces First Surgical Case of Atrix-C™ Cervical Allograft Interbody Spacer
BELGRADE, Mont., Dec. 09, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the first surgical case of the Atrix-C Cervical Allograft Interbody Spacer. This allograft spacer represents the first Xtant Medical product launched within the U.S., following the combination of Bacterin International, Inc. and X-spine Systems, Inc., highlighting the strategic focus on co-development... 
More

Upcoming Events
DateTitle
02/10/16 10:15 a.m. ET
Xtant Medical Holdings Inc at the Source Capital 2016 Disruptive Growth & Healthcare Conference
More

Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your e-mail address and click Submit.